Lincoln Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lincoln Pharmaceuticals has submitted a mandatory compliance certificate for Q4 FY2026 (ending March 31, 2026). The filing confirms that their Registrar & Share Transfer Agent, MUFG Intime India Private Limited, properly processed all securities received for dematerialisation during the quarter. The RTA certified that share certificates were mutilated and cancelled after verification, and depository names were updated in the register of members within the prescribed timelines as required under SEBI regulations. This is a routine quarterly regulatory filing with no material corporate developments.
No direct impact on stock price or shareholder value. This is a standard SEBI-mandated compliance filing confirming proper handling of dematerialisation requests. Such routine filings typically do not influence investor decisions or stock performance.